PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02905942|
Recruitment Status : Unknown
Verified September 2016 by Jun Zhu, Peking University.
Recruitment status was: Recruiting
First Posted : September 19, 2016
Last Update Posted : September 19, 2016
|Condition or disease||Intervention/treatment||Phase|
|Lymphoma||Drug: PEG-rhG-CSF Drug: rhG-CSF||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||96 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Single Center Randomized Controlled Trial of the Efficacy and Safety of PEG-rhG-CSF After Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Patients|
|Study Start Date :||December 2015|
|Estimated Primary Completion Date :||December 2018|
Patients in PEG-rhG-CSF group received PEG-rhG-CSF day +1 after transplantation.
PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 100μg/kg(bw).For patients more than 45kg, 6mg was suggested.
Active Comparator: rhG-CSF
Patients in control group received rhG-CSF day +1 after transplantation.
rhG-CSF was given day +1 after transplantation with a dose of 5μg/kg once per day
- Time to neutrophil engraftment [ Time Frame: 30days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02905942
|Contact: Jun Zhu, MDemail@example.com|
|Peking University Cancer Hospital||Recruiting|
|Beijing, China, 100142|
|Contact: Jun Zhu, MD +86-10-88196596 firstname.lastname@example.org|
|Principal Investigator:||Jun Zhu||Beijing Cancer Hospital|